EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor ( NPY1R ) and galanin receptor 2 ( GALR2 ) agonists in the ventral hippocampus

Rasiel Beltran-Casanueva, Aracelis Hernández-García iD, Pedro Jesús Serrano-Castro iD, Jose Andrés Sánchez-Pérez iD, Miguel Angel Barbancho-Fernández iD, Natalia García-Casares iD, Kjell Fuxe iD, Dasiel O Borroto-Escuela iD, Manuel Narváez iD

The FASEB Journal · 2024

DOI: 10.1096/fj.202400087r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Rasiel Beltran-Casanueva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Neuropeptide Y, Neuropeptides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Andalusian Board | Consejería de Salud y Consumo, Junta de Andalucía (CSC), Royal Swedish Academy of Sciences (KVA), Åhlén-stiftelsen (Åhlén Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluates the sustained antidepressant‐like effects and neurogenic potential of a 3‐day intranasal co‐administration regimen of galanin receptor 2 (GALR2) agonist M1145 and neuropeptide Y Y1 receptor (NPY1R) agonist [Leu31, Pro34]NPY in the ventral hippocampus of adult rats, with outcomes analyzed 3 weeks post‐treatment. Utilizing the forced swimming test (FST), we found that this co‐administration significantly enhances antidepressant‐like behaviors, an effect neutralized by the GALR2 antagonist M871, highlighting the synergistic potential of these neuropeptides in modulating mood‐related behaviors. In situ proximity ligation assay (PLA) indicated a significant increase in GALR2/NPYY1R heteroreceptor complexes in the ventral hippocampal dentate gyrus, suggesting a molecular basis for the behavioral outcomes observed. Moreover, proliferating cell nuclear antigen (PCNA) immunolabeling revealed increased cell proliferation in the subgranular zone of the dentate gyrus, specifically in neuroblasts as evidenced by co‐labeling with doublecortin (DCX), without affecting quiescent neural progenitors or astrocytes. The study also noted a significant uptick in the number of DCX‐positive cells and alterations in dendritic morphology in the ventral hippocampus, indicative of enhanced neuronal differentiation and maturation. These morphological changes highlight the potential of these agonists to facilitate the functional integration of new neurons into existing neural circuits. By demonstrating the long‐lasting effects of a brief, 3‐day intranasal administration of GALR2 and NPY1R agonists, our findings contribute significantly to the understanding of neuropeptide‐mediated neuroplasticity and herald novel therapeutic strategies for the treatment of depression and related mood disorders, emphasizing the therapeutic promise of targeting neurogenesis and neuronal maturation processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuropeptide YNeuropeptidesRatsAnimalsReceptor, Galanin, Type 2Administration, IntranasalGalaninHippocampusReceptors, Neuropeptide YAntidepressive AgentsNeurogenesis

Stichwörter der Autor:innen

antidepressantgalanin receptor 2hippocampusintranasal administrationneurogenesisneuronal differentiationneuropeptide Y Y1 receptor

Substanzen

Neuropeptide YReceptor, Galanin, Type 2GalaninReceptors, Neuropeptide YNeuropeptidesAntidepressive Agents

Autor:innen und Institutionen

  • Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Receptomics and Brain Disorders Lab, Edificio Lopez-Peñalver, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
  • Departamento de Docencia e Investigación, Universidad de Ciencias Médicas de Holguín, Hospital Pedíatrico Universitario Octavio de la Concepción de la Pedraja, Holguín, Cuba.
  • Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
  • Instituto de Investigación Biomédica de Málaga, Unit of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Vithas Málaga, Grupo Hospitalario Vithas, Málaga, Spain.

ORCID-Profile: Aracelis Hernández-García, Pedro Jesús Serrano-Castro, Jose Andrés Sánchez-Pérez, Miguel Angel Barbancho-Fernández, Natalia García-Casares, Kjell Fuxe, Dasiel O Borroto-Escuela, Manuel Narváez

Förderung

  • Andalusian Board | Consejería de Salud y Consumo, Junta de Andalucía (CSC)
  • Royal Swedish Academy of Sciences (KVA)
  • Åhlén-stiftelsen (Åhlén Foundation)
  • Hjärnfonden
  • Ministerio de ciencia, Innovación y universidades

Zitieren

APA

Beltran-Casanueva, R., Hernández-García, A., Serrano-Castro, P. J., Sánchez-Pérez, J. A., Barbancho-Fernández, M. A., García-Casares, N., Fuxe, K., Borroto-Escuela, D. O., & Narváez, M. (2024). Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor ( NPY1R ) and galanin receptor 2 ( GALR2 ) agonists in the ventral hippocampus. The FASEB Journal. https://doi.org/10.1096/fj.202400087r

Vancouver

Beltran-Casanueva R, Hernández-García A, Serrano-Castro PJ, Sánchez-Pérez JA, Barbancho-Fernández MA, García-Casares N, et al. Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor ( NPY1R ) and galanin receptor 2 ( GALR2 ) agonists in the ventral hippocampus. The FASEB Journal. 2024. doi:10.1096/fj.202400087r

BibTeX
@article{BeltranCasanueva2024,
  author = {Beltran-Casanueva, Rasiel and Hernández-García, Aracelis and Serrano-Castro, Pedro Jesús and Sánchez-Pérez, Jose Andrés and Barbancho-Fernández, Miguel Angel and García-Casares, Natalia and Fuxe, Kjell and Borroto-Escuela, Dasiel O and Narváez, Manuel},
  title = {Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor ( NPY1R ) and galanin receptor 2 ( GALR2 ) agonists in the ventral hippocampus},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202400087r}
}
Kostenlos starten →